The radiolabelled small molecule lutetium-177 (177Lu)-PSMA617 can target radiotherapy to prostate-specific membrane antigen-positive prostate cancer cells. In a phase 2 trial led by Michael Hofman (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia), 30 patients with PSMA-avid refractory metastatic castration-resistant prostate received up to four cycles of LuPSMA every 6 weeks. The coprimary endpoints were reduction in prostate-specific antigen (PSA), response on FDG imaging, and toxicity.

中文翻译：

---

ESMO 2017大会

放射性标记的小分子-177（177Lu）-PSMA617可以将放射疗法靶向前列腺特异性膜抗原阳性的前列腺癌细胞。在迈克尔·霍夫曼（Michael Hofman）（澳大利亚维多利亚州墨尔本的彼德·麦克卡勒姆癌症中心）领导的一项2期试验中，每6周有30例PSMA-avid难治性转移去势抵抗性前列腺癌患者接受了多达四个疗程的LuPSMA。共同的主要终点是前列腺特异性抗原（PSA）减少，FDG成像反应和毒性。